Elan Pharmaceuticals, Inc.

Elizabeth Messersmith

Andrei William Konradi

Michael A Pleiss

Theodore A Yednock

Stephen B Freedman

Ivan Lieberburg

Christopher Michael Semko

Darren B Dressen

Lisa Claire McConlogue

Kate Dora Games

Ted A Yednock

Francine S Farouz

George Shopp

Stephen J Karlik

Tan Hua

The application relates to a method of using compositions having anti-alpha-4 integrin and/or anti-alpha-9 integrin activity to inhibit liquid tumor growth, malignancies thereof and/or development of metastases thereof that involve expression of an alpha-4 integrin and/or alpha-9 integrin. Pharmaceutical compositions and combination therapies (for example, with chemotherapies) for the inhibition of liquid tumor growth, malignancies thereof and/or development of metastases thereof are also provided.

Methods and compositions for treating liquid tumors

This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (&#x3b1;4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.

Methods and compositions for treating rheumatoid arthritis

The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.

Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology associated with Alzheimer's Disease.

Selecting compounds to reduce inflammation associated with Alzheimer's disease

Growing community of inventors

El Cerrito, CA, United States of America

Elizabeth Messersmith